
Roger Stupp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5020947/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
2	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials. Clinical Cancer Research, 2022, 28, 129-136.	7.0	25
3	Leptomeningeal metastases: the future is now. Journal of Neuro-Oncology, 2022, 156, 443-452.	2.9	11
4	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. Neuro-Oncology, 2022, 24, 1533-1545.	1.2	13
5	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1269-1278.	0.8	20
6	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24, 2159-2169.	1.2	7
7	Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. Clinical Cancer Research, 2022, 28, 3156-3169.	7.0	4
8	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	1
9	Role of Resection in Glioblastoma Management. Neurosurgery Clinics of North America, 2021, 32, 9-22.	1.7	14
10	Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. Journal of Experimental Medicine, 2021, 218, .	8.5	42
11	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 2021, 23, 1327-1336.	1.2	15
12	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Molecular Cell, 2021, 81, 1276-1291.e9.	9.7	54
13	<i>De novo</i> purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain, 2021, 144, 1230-1246.	7.6	30
14	<i>MGMT</i> promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. Neuro-Oncology, 2021, 23, 858-860.	1.2	8
15	Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. Neuro-Oncology Practice, 2021, 8, 581-588.	1.6	0
16	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncology, The, 2021, 22, 1103-1114.	10.7	91
17	EXTH-36. ELECTROCONVULSIVE SEIZURE-INDUCED CHANGES IN THE TUMOR MICROENVIRONMENT PROMOTE SURVIVAL IN GLIOMA-BEARING MICE. Neuro-Oncology, 2021, 23, vi171-vi171.	1.2	0
18	BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi17-vi17.	1.2	0

#	Article	IF	CITATIONS
19	INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY. Neuro-Oncology, 2021, 23, vi107-vi108.	1.2	0
20	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39
21	CTNI-47. INTERIM RESULTS OF NCT03011671: A MULTI-INSTITUTIONAL PHASE I STUDY OF ACETAZOLAMIDE WITH TEMOZOLOMIDE IN ADULTS WITH NEWLY DIAGNOSED MGMT-METHYLATED MALIGNANT GLIOMA. Neuro-Oncology, 2021, 23, vi70-vi70.	1.2	1
22	IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE. Neuro-Oncology, 2021, 23, vi98-vi98.	1.2	0
23	BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi17-vi18.	1.2	0
24	EXTH-29. DUAL TGFB AND PD1 BLOCKADE PROMOTES GERMINAL-CENTER B-CELL IMMUNE RESPONSES AGAINST GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi169-vi169.	1.2	1
25	Ultrasound-mediated Blood-brain barrier opening increases cell-free DNA in a time dependent manner. Neuro-Oncology Advances, 2021, 3, vdab165.	0.7	5
26	CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi52.	1.2	3
27	TMOD-08. DEVELOPING DERIVATIVE GBM PDX, IN VIVO, FROM TREATMENT NAÃVE SOURCES. Neuro-Oncology, 2021, 23, vi217-vi217.	1.2	0
28	Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. International Journal of Cancer, 2020, 146, 803-809.	5.1	42
29	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49
30	Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clinical Cancer Research, 2020, 26, 477-486.	7.0	98
31	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neuro-Oncology Practice, 2020, 7, 668-675.	1.6	5
32	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
33	Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue. BMC Cancer, 2020, 20, 458.	2.6	0
34	Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene, 2020, 39, 5068-5081.	5.9	21
35	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
36	Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene, 2020, 39, 4132-4154.	5.9	23

#	Article	IF	CITATIONS
37	Leptomeningeal metastasis from solid tumors. Journal of the Neurological Sciences, 2020, 411, 116706.	0.6	34
38	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Neuro-Oncology Advances, 2020, 2, vdaa147.	0.7	1
39	CTNI-31. INTERIM RESULTS OF A PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BBB OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO IV CARBOPLATIN. Neuro-Oncology, 2020, 22, ii49-ii49.	1.2	1
40	Are Integrins Still Practicable Targets for Anti-Cancer Therapy?. Cancers, 2019, 11, 978.	3.7	128
41	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro-Oncology, 2019, 21, 1447-1457.	1.2	35
42	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
43	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 116, 190-198.	2.8	22
44	Overcoming the Blood–Brain Barrier with an Implantable Ultrasound Device. Clinical Cancer Research, 2019, 25, 3750-3752.	7.0	18
45	Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. International Journal of Radiation Oncology Biology Physics, 2019, 104, 90-100.	0.8	20
46	ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN. Neuro-Oncology, 2019, 21, vi26-vi27.	1.2	0
47	CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. Neuro-Oncology, 2019, 21, vi53-vi53.	1.2	0
48	QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. Neuro-Oncology, 2019, 21, vi197-vi198.	1.2	1
49	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. Neuro-Oncology, 2019, 21, vi198-vi198.	1.2	0
50	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178.	1.2	173
51	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. Journal of Neuro-Oncology, 2019, 141, 111-120.	2.9	24
52	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of Thoracic Oncology, 2019, 14, 115-123.	1.1	21
53	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research, 2019, 25, 1809-1816.	7.0	94
54	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clinical Cancer Research, 2018, 24, 2559-2573.	7.0	147

#	Article	IF	CITATIONS
55	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
56	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	7.7	76
57	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	7.1	135
58	CAR T-Cell Therapies in Glioblastoma: A First Look. Clinical Cancer Research, 2018, 24, 535-540.	7.0	103
59	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. Neuro-Oncology, 2018, 20, vi221-vi221.	1.2	0
60	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. Neuro-Oncology, 2018, 20, vi216-vi216.	1.2	1
61	CSIG-18. MODELING TEMOZOLOMIDE RESISTANCE WITH GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS. Neuro-Oncology, 2018, 20, vi46-vi47.	1.2	0
62	ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA,) TJ ETO	Qq ହ.୭ ୦ rg	;BT1/Overlock
63	CSIG-35. MST4 PHOSPHORYLATION OF ATG4B REGULATES AUTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi50-vi51.	1.2	0
64	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV― Acta Neuropathologica, 2018, 136, 805-810.	7.7	599
65	B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. Diagnostic Pathology, 2018, 13, 37.	2.0	7
66	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
67	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	137
68	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	107
69	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
70	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clinical Cancer Research, 2017, 23, 6650-6660.	7.0	141
71	Evidence-based management of adult patients with diffuse glioma – Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5
72	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307

#	Article	IF	CITATIONS
73	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell, 2017, 32, 840-855.e8.	16.8	188
74	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
75	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA - Journal of the American Medical Association, 2017, 318, 2306.	7.4	1,619
76	IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL. Neuro-Oncology, 2017, 19, vi117-vi117.	1.2	0
77	Corticosteroids compromise survival in glioblastoma. Brain, 2016, 139, 1458-1471.	7.6	271
78	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
79	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	10.7	396
80	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535.	7.4	982
81	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 2015, 16, 16.	8.8	82
82	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, The, 2015, 386, 1049-1056.	13.7	316
83	Withholding temozolomide in glioblastoma patients with unmethylated <i>MGMT</i> promoter—still a dilemma?: Table 1 Neuro-Oncology, 2015, 17, 1425-1427.	1.2	78
84	Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial Journal of Clinical Oncology, 2015, 33, 2000-2000.	1.6	16
85	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROC/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma Journal of Clinical Oncology, 2015, 33, 2006-2006.	1.6	7
86	The accuracy of predicting survival in individual patients with cancer. Journal of Neurosurgery, 2014, 120, 24-30.	1.6	113
87	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
88	PET Imaging in Glioma. PET Clinics, 2013, 8, 117-128.	3.0	4
89	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 916-926.	10.7	1,075
90	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	10.7	6,451

#	Article	IF	CITATIONS
91	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncology, The, 2009, 10, 785-793.	10.7	106
92	Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. Journal of Clinical Oncology, 2007, 25, 4127-4136.	1.6	474
93	Anaplastic astrocytoma in adults. Critical Reviews in Oncology/Hematology, 2007, 63, 72-80.	4.4	67
94	Neuro-oncology: oligodendroglioma and molecular markers. Lancet Neurology, The, 2007, 6, 10-12.	10.2	6
95	Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Clioblastoma Multiforme. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 37-52.	0.0	2
96	Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma. Oncologist, 2006, 11, 165-180.	3.7	357
97	Optimal role of temozolomide in the treatment of malignant gliomas. Current Neurology and Neuroscience Reports, 2005, 5, 198-206.	4.2	168
98	<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine, 2005, 352, 997-1003.	27.0	6,573
99	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 2005, 352, 987-996.	27.0	17,395
100	Small cell lung cancer: state of the art and future perspectives. Lung Cancer, 2004, 45, 105-117.	2.0	150
101	Prognostic factors for low-grade gliomas. Seminars in Oncology, 2003, 30, 23-28.	2.2	52
102	Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. Journal of Clinical Oncology, 2002, 20, 1375-1382.	1.6	703
103	Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. , 0, , 37-52.		1